SCHEMBL1103918

SCHEMBL1103918

Cc1cccc2c1Nc1c(-c3ccccc3-c3cccc(C(N)=O)c3)nc3cccc-2n13

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 1/20 0.38
BAZ2A Q9UIF9 1/20 0.38
BRD4 O60885 2/20 0.38
DYRK1A Q13627 2/20 0.38
CREBBP Q92793 1/20 0.38
LRRK2 Q5S007 1/20 0.38
NR1H4 Q96RI1 1/20 0.37
MAP2K4 P45985 1/20 0.37
PDK2 Q15119 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
AKT1 P31749 2/20 0.36
AKT2 P31751 2/20 0.36
PRKCI P41743 1/20 0.35
PDE2A O00408 2/20 0.35
PDE10A Q9Y233 2/20 0.35
PDE4D Q08499 1/20 0.35
PDE3A Q14432 1/20 0.35
FYN P06241 3/20 0.35
NR4A2 P43354 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1104524 0.91 NR1H4 (0.44) NR1H4MAP2K4PDK2NPC1RAB9A
SCHEMBL1097764 0.71 GAA (0.54) BAZ2BBAZ2ANTRK1MAPK1
SCHEMBL3636122 0.70 NR1H4 (0.56) BAZ2BBAZ2ABRD4DYRK1ACREBBP
SCHEMBL3135455 0.67 PARP1 (0.53) BAZ2BBAZ2ABRD4DYRK1ACREBBP
SCHEMBL5307077 0.66 PARP1 (0.56) BAZ2BBAZ2ADYRK1APDK2NPC1
Hydrochloric Acid SCHEMBL29287792 0.65 PARP1 (0.51) BAZ2BBAZ2ABRD4DYRK1ACREBBP
Hydrochloric Acid SCHEMBL29287827 0.65 PARP1 (0.51) BAZ2BBAZ2ABRD4DYRK1ACREBBP
SCHEMBL12820218 0.64 ADORA2A (0.55) BAZ2BBAZ2ADYRK1ANR1H4MAP2K4
SCHEMBL4262253 0.63 PARP1 (0.60) BAZ2BBAZ2ALRRK2MAP2K4CSF1R
Trifluoroacetic Acid SCHEMBL1785131 0.63 NR1H4 (0.51) BAZ2BBAZ2ABRD4LRRK2NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153649-B2 3-aminoimidazo 1,2-A pyridine derivatives having an SGLT1- and SGLT2-inhibiting action for the treatment of type 1 and type 2 diabetes MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-04-10 US disclosed
US-20100305142-A1 3-AMINOIMIDAZO 1,2-A PYRIDINE DERIVATIVES HAVING AN SGLT1- AND SGLT2-INHIBITING ACTION FOR THE TREATMENT OF TYPE 1 AND TYPE 2 DIABETES MERCK PATENT GESELLSCHAFT (DE) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305142-A1 3-AMINOIMIDAZO 1,2-A PYRIDINE DERIVATIVES HAVING AN SGLT1- AND SGLT2-INHIBITING ACTION FOR THE TREATMENT OF TYPE 1 AND TYPE 2 DIABETES SLC5A1, SLC5A2, GLP1R BAZ2B 3703/4885BAZ2A 3189/4885BRD4 1512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.